Latest news about Jenburkt Pharmaceuticals
Jenburkt Pharmaceuticals
1,091.60
+0.85(+0.08%)
Company Performance:
View Company Insights1D+0.08%
1M-2.21%
6M-1.16%
1Y-13.51%
5Y+114.95%
More news about Jenburkt Pharmaceuticals
07Apr 26
Jenburkt Pharmaceuticals Files Quarterly Compliance Certificate for Q4 FY26
Jenburkt Pharmaceuticals Ltd has submitted its quarterly compliance certificate to BSE Ltd for Q4 FY26 ended March 31, 2026. The certificate, issued by registrar Bigshare Services Pvt. Ltd., confirms compliance with SEBI Regulation 74(5) regarding dematerialization processes. The filing demonstrates the company's adherence to regulatory requirements and proper handling of securities transactions during the quarter.
03Feb 26
Jenburkt Pharmaceuticals Reports Q3FY26 Results with Revenue of Rs 4302.39 Lacs
Jenburkt Pharmaceuticals reported Q3FY26 revenue from operations of Rs 4302.39 lacs, up 16.63% year-over-year but down from Rs 4555.76 lacs in Q2FY26. Net profit declined to Rs 593.14 lacs from Rs 650.75 lacs in Q3FY25. Nine-month performance showed revenue growth of 12.17% to Rs 12410.83 lacs and net profit increase of 1.54% to Rs 2388.66 lacs. The results were approved by the Board on February 3, 2026.
28Oct 25
Jenburkt Pharmaceuticals Reports 10.5% Revenue Growth in Q2 FY2026
Jenburkt Pharmaceuticals Limited announced strong Q2 FY2026 results. Revenue from operations increased by 10.5% to Rs 4,555.70 lacs, while profit after tax grew by 11.3% to Rs 1,133.20 lacs compared to Q2 FY2025. Total income rose by 10.6% to Rs 4,763.66 lacs. For the half-year ended September 30, 2025, total revenue reached Rs 8,108.40 lacs, a 10% increase from the previous year. The company continues to focus exclusively on the pharmaceuticals segment. The Board of Directors approved these unaudited financial results on October 28, 2025, following a limited audit review by D.R. Mehta & Associates.
20May 25
Jenburkt Pharmaceuticals Reports Strong Q4 Results, Announces Dividend
Jenburkt Pharmaceuticals released its Q4 financial results, showing significant growth. Revenue increased by 5.80% to ₹410.50 crore. EBITDA rose by 10.25% to ₹108.60 crore, with the EBITDA margin expanding to 26.45%. Net profit grew by 8.10% to ₹85.40 crore. The company also announced a dividend of ₹18.00 per equity share.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Mankind Pharma
Laurus Labs
Dr Reddys Laboratories
Aurobindo Pharma
1,964.00
(+0.03%)
8,378.00
(-2.41%)
5,030.00
(-0.40%)
1,460.00
(-0.98%)
1,130.00
(+0.80%)
2,410.00
(+0.71%)
2,438.00
(-1.81%)
1,850.00
(+2.13%)
1,172.60
(-0.63%)
1,585.90
(+2.01%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
